Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

About

Brief Summary

This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.

Study Type

Observational

Phase

N/A

Eligibility

Gender

All

Healthy Volunteers

Minimum Age

N/A

Maximum Age

N/A

Inclusion Criteria:

The patient must be enrolled on a frontline COG therapeutic trial for treatment of a primary malignancy;or the patient must have been enrolled on a COG (or Legacy Group) therapeutic or non-therapeutic trial targeted for long-term follow-up by ALTE05N1
- Hodgkin lymphoma
  - CCG 5942
  - POG 9425
  - POG 9426
  - AHOD0031
  - AHOD1331
  - S1826 (COG patients only)
- Brain tumor
  - A9961
- Acute lymphoblastic leukemia
  - POG 9404
- Osteosarcoma
  - POG 9754
- Stem cell transplantation
  - ASCT0631D
- Rhabdomyosarcoma
  - IRS-III
  - IRS-IV
- Late Effects Protocols with Patients Eligible for Enrollment on ALTE05N1
  - ALTE15N1
  - ALTE16C1
- Enrollment on ALTE05N1 must occur within 24 calendar months of the date the patient was enrolled on a frontline COG therapeutic trial; or patients previously enrolled on a COG (or Legacy Group) trial targeted for long term follow-up by ALTE05N1 may enroll on ALTE05N1 at any time
The patient must reside in the U.S. on the date of enrollment to ALTE05N1
All patients and/or their parents or legal guardians must sign a written informed consent
All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you